GlassScriptPhysician profile
Jorge L Mena
NPI 1891233037
$27,200.54
in general payments reported to CMS, 2019-2025
38 companies · $2,052 in 2025
The $2,052 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,789 · 2022: $16K · 2023: $395 · 2024: $3,285 · 2025: $2,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245 · Long Term Medical Supply Or Device Loan: $2,196 · Consulting Fee: $800 · Education: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,245.38 |
| Long Term Medical Supply Or Device Loan | $2,196.36 |
| Consulting Fee | $800.00 |
| Education | $490.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $20,473.87 | 2021-2024 | Rezlidhia, Tavalisse |
| Novartis Pharmaceuticals Corporation | $2,486.78 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,265.28 | 2024-2025 | Enhertu, Imfinzi, Calquence |
| Cti Biopharma Corp. | $700.00 | 2022 | |
| Incyte Corporation | $590.45 | 2021-2025 | Jakafi, Monjuvi |
| Sobi, INC | $174.80 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $149.98 | 2022-2023 | |
| Genzyme Corporation | $110.81 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.01 | 2024-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Daiichi Sankyo INC. | $96.45 | 2024-2025 | Enhertu |
| Janssen Biotech, INC. | $95.15 | 2024-2025 | Rybrevant, Talvey, Carvykti |
| Pfizer INC. | $94.35 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $88.38 | 2024-2025 | Keytruda, Reblozyl, Lynparza |
| Apellis Pharmaceuticals, INC. | $71.14 | 2023 | Empaveli |
| Genentech USA, INC. | $68.41 | 2024-2025 | Itovebi, Polivy, Lunsumio |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Mena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.